Key Takeaways
- Recovery underway, FDA overhang persists: Revenue of ₹403 crores and EBITDA margin of 9.2% reflect a business transitioning from regulatory disruption to execution-led growth, though substantial remediation costs continue to depress profitability in this transition year.
- Pharma is the engine, Crop is the drag: Pharma delivered YoY growth with improving margins, while Crop Protection margins remain under pressure from elevated raw material costs and Chinese pricing, with CDMO orders deferred.
- Full-year guidance implies sharp acceleration: Management expects 14–16% revenue growth and 25–30% EBITDA growth for FY27, implying a significant H2 ramp driven by CDMO contribution and recovery in regulated markets.
- Strategic pivot away from Crop is now explicit: The impaired agrochemical plant is being retooled for Pharma/Animal Health, and management stated it is not investing significant new capital in Crop, expecting only marginal growth from the division.[10-11]
- What to watch next quarter: Whether the promised substantial YoY growth in Q2 materializes, the trajectory of raw material costs, and any update on the timing of the U.S. FDA re-inspection.[12-13]
Pharma & CDMO: The Growth Driver
- Regulatory recovery on track: U.S. FDA remediation is almost complete, with re-inspection expected towards the end of FY27, though management acknowledges it may be delayed by a few months. Over 86 customer audits and three major global regulatory inspections have re-approved facilities in the last 12 months.[13-14]
- Zero customer loss: No single customer order was lost in the last 12 months, a fact management emphasized repeatedly as evidence of sustained client confidence despite the regulatory overhang.
- Capacity utilization improving: Panoli and Bangalore facilities operated at nearly 55–60% average capacity utilization, reflecting improving business momentum, with further ramp expected as DMF filings accelerate.
- CDMO pipeline building: Discussions with a leading Japanese innovator are progressing well, and the new cGMP pilot plant in Panoli de-risks operations while enabling DMF filing rates to increase to 5–6 per year from 2–3 historically.
- Post-FDA growth trajectory: Once FDA clearance is obtained, pending filings will be submitted and revenues are expected to ramp in FY28, supporting an 18–19% pharma CAGR that could accelerate further if some of the NCE filings that are pending ramp up.
- Geographic expansion: The company expects to further expand presence in Latin America, Japan, and South Korea, supported by four dedicated business development hires across Japan, North America, and Europe.
Hiremath: "We haven’t lost a single customer order in the last 12 months."
Crop Protection: Managed for Cash, Not Growth
- Mixed quarter with margin pressure: Own product segment delivered sequential volume growth supported by improving domestic demand, but EBITDA was impacted by nearly ₹7–8 crores of elevated raw material and fuel costs from Middle East geopolitical developments, plus continued pricing pressure from China.
- CDMO orders deferred: Export demand remained subdued with certain customer orders pushed to subsequent quarters due to inventory build-up at the customer end, though these are expected to be executed in H2.
- Industry recovering, but only on volumes: Global channel inventories have largely normalized after two years of destocking, but distributors are buying just-in-time rather than restocking, and surplus Chinese supply keeps pricing under pressure. The recovery is volume-driven, not pricing-driven.
- Capital allocation pivot made explicit: Management stated it expects only marginal growth from Crop going forward and is not investing significant new capital in the division, instead managing it for healthy cash flows with strict financial discipline. [10-11]
- Near-term outlook: Q2 is expected to be better than Q1, supported by the Indian Kharif season, with further improvement in Q3 from the Rabi season and Latin American demand, though margins may remain under pressure in the near term.
Animal Health & Personal Care: The Diversification Bet
- Animal Health momentum: Delivered another strong quarter with healthy volume growth across the API and intermediate segment, supported by repeat NCE campaign supplies for a leading innovator and commercialization of new molecules.
- Dedicated infrastructure paying off: The ₹150 crores dedicated Animal Health manufacturing site has completed validations and started generating revenue, while U.S. EPA and Canada PMRA regulatory filings for a particular molecule were completed during Q1 FY27.
- ₹400 crores-plus ambition by FY30: Management remains confident of scaling the business to that level, with 20%+ EBITDA margins expected once operational leverage is reached, supported by CDMO contracts signed and being finalized with global customers.
- Personal Care launch underway: A dedicated multi-purpose manufacturing line at Panoli has been commissioned and commercial production has commenced, with first revenue expected by the end of this year. The business is targeted to cross ₹200 crores in revenue in the next three years with EBITDA margins over 20%.
- Strategic partnerships progressing: Discussions on strategic partnerships with several Japanese companies in Animal Health are progressing well, further strengthening the future growth pipeline.
Asset Retooling & Capital Allocation
- Impaired agrochemical plant repurposed: The ₹300 crores plant, part-impaired in Q4 FY26, is being retooled for new Pharma and Animal Health CDMO contracts, reducing execution timelines by nearly 12 months versus building new capacity.
- Bangalore multipurpose facility: ₹100 crores invested over the last three years has already started generating revenue, adding to the pharma and allied manufacturing base.
- R&D infrastructure upgraded: New high-potency anti-cancer laboratory in Pune, a new cGMP pilot plant, and a new pilot plant in Panoli have been commissioned, positioning the company for emerging opportunities in high-potency APIs, ADC linkers, and payloads.
- Debt reduction despite investment cycle: Net debt reduced from ~₹815 crores in FY24 to ₹685 crores by FY26, with a debt-to-equity ratio of 0.53, achieved while navigating a challenging business environment and completing significant capex.
- Portfolio mix shifting decisively: In the next 2–3 years, pharma and allied businesses (human, animal health, personal care) are expected to represent 70–80% of total business, with Crop at about 30%.
Hiremath: "We are expecting very marginal growth in the crop division. That's why we have diversified into allied businesses. We are not investing a significant amount of new capital in the crop business." [10-11]
Margins & Cost Structure
- Q1 margin depressed by dual headwinds: EBITDA margin of 9.2% reflects the combined impact of substantial FDA remediation costs hitting fixed costs and a ₹7–8 crores raw material increase in the Crop division from elevated energy prices.
- Remediation costs are temporary: Management characterized FY27 as a transition year where remediation costs are depressing EBITDA, with the benefit flowing to the P&L once the FDA re-inspection is completed, expected by end of this year or early next.
- Raw material volatility a wildcard: Management expects oil price declines to normalize raw material costs by end of Q2, but acknowledged that if geopolitical conflict escalates, prices could rise again. [12-13]
- Operating leverage to drive recovery: As volumes recover in Pharma CDMO and Crop, and as the Animal Health and Personal Care businesses scale, operating leverage is expected to strengthen margins, with FY28 seen as a substantially better year.
- Exceptional income: ₹9 crores was recognized from reversal of excess provision made in Q4 FY26 related to new Labor Codes, due to restructuring of pay scales.
Hiremath: "This is a transition year where the FDA remediation costs are still hitting our fixed cost numbers, so it's depressing EBITDA. Once the FDA remediation goes away by end of this year, next year onwards, the EBITDAs will start improving even more substantially."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q2 FY27 performance | Substantial growth in revenues and EBITDA on a YoY basis | Q2 FY27 |
| Full-year FY27 revenue growth | Approximately 14% to 16%, with strong growth in pharma and marginal growth in crop | FY27 |
| Full-year FY27 EBITDA growth | 25% to 30% | FY27 |
| U.S. FDA re-inspection | Re-inspection expected; may be delayed by a few months | End of FY27 / early FY28 |
| DMF filing rate | Increase to 5–6 per year from 2–3 historically | FY27 and beyond |
| Personal Care first revenue | Revenue expected from the newly commissioned line | End of FY27 |
| Animal Health revenue target | Scale to ₹400 crores | By FY30 |
| Animal Health EBITDA margin | 20%+ once operational leverage is reached | At scale (undated) |
| Personal Care revenue target | Cross ₹200 crores in revenue | Within 3 years post-FY27 |
| Personal Care EBITDA margin | Over 20% | At scale (undated) |
| Pharma and allied business share | 70–80% of total business | Next 2–3 years |
| Pharma CAGR post-FDA clearance | 18–19%, possibly faster if NCE filings ramp up | FY28 onwards |
| FY28 outlook | Substantially better year than FY27; remediation cost benefit flows to P&L | FY28 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹403 cr |
| EBITDA | ₹37 cr |
| EBITDA margin | 9.2% |
| PAT | ₹(-7) cr |
| Exceptional income | ₹9 cr, reversal of excess provision for new Labour Codes |
| Pharma revenue | ₹233 cr |
| Pharma EBIT | ₹8 cr |
| Pharma EBIT margin | 3.2% |
| Crop Protection revenue | ₹170 cr |
| Crop Protection EBIT | ₹(-6) cr |
| Pharma capacity utilization | 55%–60%, Panoli and Bangalore, considering Q1 shutdowns |
| Capex during the quarter | ₹45 cr |
| Net debt | ₹685 cr, as of FY26 end, reduced from ~₹815 cr in FY24 |
| Debt-to-equity ratio | 0.53, as of June 30, 2026, vs 0.56 in March quarter |
| Full-year FY27 revenue growth guidance | ~14%–16% |
| Full-year FY27 EBITDA growth guidance | 25%–30% |
| Animal Health business FY30 revenue target | about ₹400 cr |
| Animal Health EBITDA margin target | 20% plus, once operational leverage is reached |
| Personal Care business revenue target | ~₹200 cr, in the next three years post this launch year |
| Personal Care EBITDA margin target | over 20% |
| DMF filing rate expected | 6–7 per year, up from 2–3 historically |
| Pharma CDMO pipeline | ~8–9 molecules, at various stages of development |
| Customer audits in last one year | over 86, all re-approved facilities |